Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Myelodysplastic syndromes (MDS) are heterogeneous hematologic disorders with unpredictable clinical courses.
• Accurate prediction of MDS progression is challenging due to the absence of specific molecular markers.
• SALL4 is implicated in hematopoiesis and leukemogenesis, with prior studies in mice suggesting a role in MDS development.

Purpose of the Study:

• To investigate the diagnostic and prognostic value of SALL4 expression in human myelodysplastic syndromes (MDS).
• To evaluate the correlation of SALL4 levels with MDS subtypes, disease grade, and progression to acute myeloid leukemia (AML).

Main Methods:

• Analysis of SALL4 expression levels in a cohort of 55 newly diagnosed MDS patients, 20 MDS-AML patients, and 16 post-treatment MDS patients.
• Comparison of SALL4 expression in patient samples against 10 healthy donors.
• Correlation of SALL4 expression with International Prognostic Scoring System (IPSS) scores, blast counts, cytogenetics, and survival rates.

Main Results:

• SALL4 was found to be overexpressed in MDS patients, with levels increasing proportionally with higher IPSS scores.
• SALL4 expression positively correlated with blast counts, high-risk karyotypes, and significantly increased during transformation to MDS-AML.
• Higher SALL4 levels were associated with worse survival rates, and expression decreased after effective therapy.

Conclusions:

• SALL4 is overexpressed in myelodysplastic syndromes (MDS) and its expression pattern mirrors that of Bmi-1, a known prognostic marker.
• SALL4 expression levels correlate with disease severity, progression to acute myeloid leukemia (AML), and patient survival.
• SALL4 represents a promising molecular marker for predicting the prognosis of MDS.